SEQENS makes multi-million-dollar funding in U.S. R&D laboratory

SEQENS, an built-in chief within the manufacturing of lively substances and pharmaceutical intermediates, introduced a multi-million-dollar funding in its analysis and improvement laboratory positioned in Devens, Mass. The enhancements will be sure that the brand new facility will function on the highest requirements of security and high quality, whereas additionally rising SEQENS R&D functionality and productiveness within the US strengthening its international R&D community. Completion of the challenge is anticipated in October 2022.

The funding in Devens strengthens the corporate’s U.S. operations—which additionally features a gross sales workplace and contract improvement and manufacturing operation in close by Newburyport, Mass.—and indicators SEQENS’ dedication to broadening its attain within the U.S. market. The funding comes simply three months after SK Capital grew to become a majority holder in SEQENS by merging it with its portfolio firm Wavelength Prescribed drugs to create one of many largest, most diversified contract improvement and manufacturing organizations (CDMOs) on the planet.

New traders in SEQENS, alongside SK Capital, embody Bpifrance and Nov Santé, with present shareholders Mérieux Fairness Companions, Ardian, and Eximium.

With the help of our shareholders and with the mixture of Wavelength’s applied sciences, merchandise, and acknowledged know-how, we are going to speed up the initiatives launched in latest months and additional strengthen our positions to help our prospects worldwide within the improvement of their initiatives.”

Pierre Luzeau, President, SEQENS

The addition of Wavelength broadens SEQENS’ international attain by offering manufacturing amenities in Israel and India and gross sales places of work in Europe and the U.S. It additionally broadens SEQENS’ API portfolio and its cytotoxic, steroidal, and high-potency merchandise, together with Wavelength’s experience in complicated pharmaceutical synthesis are complementary to SEQENS core competencies. In whole, the expanded portfolio now contains 200 lively pharmaceutical substances (APIs), 500 pharmaceutical intermediates, in addition to key specialty substances and chemical substances.

Along with the re-development of its Devens lab, SEQENS is investing considerably throughout the enterprise to help prospects’ progress in each its industrial and improvement merchandise and know-how platforms, together with customized polymers, lipids, circulate chemistry, excessive efficiency APIs, and biocatalysts. The corporate can be dedicated to the very best ranges of environmental, social and governance requirements, with 15 EcoVadis platinum and gold websites amongst its international built-in community, which contains 24 manufacturing websites, 10 R&D facilities, and three,200 staff positioned on 3 continents.

Source

Share

Leave a Reply